Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Efficacy and Safety of Cyclophosphamide in Pediatric Patients With Steroid-Refractory Acute Disseminated Encephalomyelitis (ADEM) (CYC-ADEM-Peds)

15. november 2026 oppdatert av: Damascus University

A Randomized, Open-Label, Comparative Clinical Trial Evaluating the Efficacy and Safety of Cyclophosphamide Versus Intravenous Immunoglobulin (IVIG) in Pediatric Patients With Steroid-Refractory Acute Disseminated Encephalomyelitis

Acute Disseminated Encephalomyelitis (ADEM) is a severe, immune-mediated demyelinating disease of the central nervous system predominantly affecting the pediatric population. Although high-dose intravenous corticosteroids (such as methylprednisolone) represent standard first-line therapy, a subset of clinical cases fails to achieve adequate clinical response, carrying high risks of persistent neurological disability, neurodevelopmental sequelae, or fulminant deterioration.

This randomized, open-label trial evaluates the clinical efficacy, neuroimaging outcomes, and safety profile of intravenous cyclophosphamide pulse therapy compared with intravenous immunoglobulin (IVIG) as a rescue modality in pediatric patients under 14 years of age with steroid-refractory ADEM. Eligible participants are allocated using a computer-based random number generator. Enrolled patients are prospectively monitored for neurological recovery, functional disability using the pediatric Liverpool Outcome Score (LOS), radiological resolution on neuroimaging (MRI), overall survival, and treatment-emergent adverse events.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Acute Disseminated Encephalomyelitis (ADEM) is an immune-mediated demyelinating inflammatory disorder of the central nervous system predominantly affecting pediatric patients. While high-dose intravenous corticosteroids (such as methylprednisolone) serve as the standard first-line treatment, a clinical subset of patients fails to respond, presenting persistent neurological deficits, neurodevelopmental sequelae, or fulminant clinical deterioration.

This prospective, randomized, open-label comparative clinical trial is designed to evaluate the therapeutic efficacy, neuroimaging resolution, and safety profile of intravenous cyclophosphamide pulse therapy compared with intravenous immunoglobulin (IVIG) as a standard second-line immunomodulatory therapy in pediatric patients under 14 years of age with steroid-refractory ADEM.

Eligible participants (a total of 30 pediatric patients) are randomized in a 1:1 ratio using a computer-generated random number sequence into two equal treatment arms: 15 patients in the experimental arm receive intravenous cyclophosphamide pulse therapy (500 mg/m2) combined with intensive hydration and Mesna uroprotection to prevent hemorrhagic cystitis, while 15 patients in the active comparator arm receive standard intravenous immunoglobulin (IVIG) immunomodulatory therapy (2 g/kg).

Longitudinal monitoring is performed across both cohorts to assess neurological functional recovery and disability using the pediatric-validated Liverpool Outcome Score (LOS), radiological clearance on brain and spine MRI, overall survival up to 24 months, and the active surveillance of treatment-emergent adverse events.

Studietype

Intervensjonell

Registrering (Antatt)

30

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Damascus, Syria
        • Rekruttering
        • Children's University Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Fatima Amer, MD
        • Hovedetterforsker:
          • Sameer Baqla, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

Ikke eldre enn 13 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Pediatric patients younger than 14 years of age (< 14 years) at clinical presentation.
  • Confirmed diagnosis of Acute Disseminated Encephalomyelitis (ADEM) fulfilling the consensus criteria defined by the International Pediatric Multiple Sclerosis Study Group (IPMSSG).
  • Steroid-refractory clinical status, defined as active disease persistence, neurological deterioration, or absence of significant functional improvement following a 3-5 day course of high-dose intravenous methylprednisolone pulse therapy (20-30 mg/kg/day).
  • Intact baseline renal function (serum creatinine and BUN within age-adjusted normal physiological ranges).
  • Intact baseline hepatic function (AST, ALT, and bilirubin within acceptable limits).
  • Absence of active systemic sepsis, bacteremia, or acute uncontrolled systemic infection at baseline.
  • Formal written informed consent obtained from parents or legal guardians.

Exclusion Criteria:

  • Patients aged 14 years and older (≥ 14.0 years).
  • Pre-existing significant renal insufficiency, acute kidney injury, or chronic renal disease.
  • Pre-existing hepatic failure, cirrhosis, or acute severe hepatic injury.
  • Active systemic sepsis or uncontrolled severe systemic infection.
  • Pre-existing severe bone marrow suppression (baseline absolute neutrophil count ANC ≤ 1500/mm³ or platelet count < 50,000/mm³).
  • History of known hypersensitivity to cyclophosphamide, Mesna, or immunoglobulin preparations.
  • Alternative neuroinflammatory or metabolic diagnosis confirmed.
  • Refusal of parents or legal guardians to grant written informed consent.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Cyclophosphamide IV

Fifteen pediatric patients (<14 years) with steroid-refractory ADEM randomized to this experimental group will receive intravenous cyclophosphamide pulse therapy as rescue treatment.

Administered as intravenous pulse therapy at a dosage of 500 mg/m² body surface area. Delivered with intensive pre- and post-hydration protocols along with Mesna (2-mercaptoethane sulfonate sodium) uroprotection to mitigate acrolein-induced hemorrhagic cystitis.

Aktiv komparator: Intravenous Immunoglobulin (IVIG)

Fifteen pediatric patients (<14 years) with steroid-refractory ADEM randomized to this active comparator group receive intravenous immunoglobulin (IVIG) as a standard second-line immunomodulatory therapy for ADEM.

Administered at a total immunomodulatory dose of 2 g/kg body weight, infused according to standard pediatric institutional protocols (either 1 g/kg/day for 2 consecutive days or 400 mg/kg/day over 5 consecutive days), under continuous hemodynamic monitoring.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Neurological Functional Outcome and Disability Assessment by Liverpool Outcome Score (LOS)
Tidsramme: Assessed at hospital discharge, and longitudinally at 2, 4, and 12 weeks post-treatment initiation.

Evaluation of functional recovery and post-encephalitic neurological sequelae using the pediatric-validated Liverpool Outcome Score (LOS). The LOS stratifies pediatric neuro-outcomes into 5 distinct categories:

  • Score 5: Full recovery (resumed normal activities / baseline abilities)
  • Score 4: Minor sequelae (mild behavioral changes or mild motor deficits with full independence)
  • Score 3: Moderate sequelae (independent in basic daily self-care but impaired in higher tasks)
  • Score 2: Major sequelae (severe physical or cognitive impairment, dependent on caregivers)
  • Score 1: Death
Assessed at hospital discharge, and longitudinally at 2, 4, and 12 weeks post-treatment initiation.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Radiological Resolution on Neuroimaging (Brain & Spine MRI)
Tidsramme: Assessed at 2,4 and 12 weeks post-treatment initiation.

Quantitative and qualitative reduction or total resolution of hyperintense demyelinating lesions on T2/FLAIR sequences, resolution of contrast enhancement, and absence of new active or demyelinating lesions.

Assessed at 2,4 and 12 weeks post-treatment initiation.
Overall Survival and All-Cause Mortality Rate
Tidsramme: Up to 24 months

Proportion of pediatric patients surviving without fatal disease complications or fulminant progression throughout the study observation window.

Up to 24 months
Treatment-Emergent Adverse Events & Tolerability
Tidsramme: Inpatient stay and longitudinally at 1, 2, and 12 weeks post-treatment initiation.

Incidence and severity of adverse drug reactions including bone marrow suppression (CBC) and hemorrhagic cystitis (Urinalysis)

Inpatient stay and longitudinally at 1, 2, and 12 weeks post-treatment initiation.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Fatima Amer, MD, Department of Pediatric Neurology, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic
  • Studieleder: Sameer Baqla, PhD, Department of Pediatric Neurology, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic
  • Studieleder: Sally Kadoura, PhD, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syrian Arab Republic

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. mars 2025

Primær fullføring (Antatt)

17. februar 2027

Studiet fullført (Antatt)

17. mars 2027

Datoer for studieregistrering

Først innsendt

15. november 2026

Først innsendt som oppfylte QC-kriteriene

15. november 2026

Først lagt ut (Faktiske)

19. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .